Showing results (231-240 of 630) with videos related to
Sort By:
Pageof 63
JACC. Cardiovascular Interventions|August 6, 2021
Antithrombotic Therapy After Transcatheter Aortic Valve ReplacementDavide Capodanno, Jean-Philippe Collet, George Dangas, et al.Stroke|January 5, 2008
A systematic review of outcomes in patients with staged carotid artery stenting and coronary artery bypass graft surgeryLuis A Guzman, Marco A Costa, Dominick J Angiolillo, et al.Circulation. Cardiovascular Interventions|July 9, 2015
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot StudyRon Waksman, Juan Maya, Dominick J Angiolillo, et al.Journal of the American College of Cardiology|April 10, 2007
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectivesDominick J Angiolillo, Antonio Fernandez-Ortiz, Esther Bernardo, et al.JACC. Case Reports|October 10, 2025
Sudden Cardiac Arrest on the Treadmill: Anomalous Left Main Mimicking Spontaneous Coronary Artery DissectionThomas Diamond, Cesar Joel Benites-Moya, Abhinav Karan, et al.Journal of the American Heart Association|April 21, 2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC StudyFrancesco Franchi, Fabiana Rollini, Gabriel Faz, et al.Expert Review of Cardiovascular Therapy|November 3, 2023
Bivalirudin in acute coronary syndromesMattia Galli, Marco Bernardi, Luis Ortega-Paz, et al.Thrombosis and Haemostasis|February 16, 2018
Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet ReactivityLaura Alemanno, Isabella Massimi, Vanessa Klaus, et al.American Heart Journal|August 3, 2020
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trialYi Li, Quanmin Jing, Bing Wang, et al.Expert Opinion on Drug Safety|November 10, 2025
Safety and optimal use of direct oral anticoagulant therapyClaudio Laudani, Luis Ortega-Paz, Ali Zgheib, et al.Pageof 63